Cancer Tumor Profiling Market by Product & Service Offering (Instruments/Systems, Assays/Kits, Services), Technology (NGS, PCR, IHC, ISH/FISH), Sample Type (Tissue, Blood, Bone Marrow), Application, Cancer Type, End User & Region – Global Forecast to 2031
The cancer tumor profiling market is projected to reach USD 19.87 billion by 2031 from USD 12.02 billion in 2026, at a CAGR of 10.6%. The global cancer tumor profiling market is projected to witness strong growth during the forecast period, supported by rising cancer incidence, increasing approvals of targeted therapies and immunotherapies, and growing integration of molecular profiling into routine oncology care. Market expansion is further supported by advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), liquid biopsy, and bioinformatics, along with increasing demand for comprehensive tumor characterization, treatment selection, treatment-response monitoring, recurrence detection, and biomarker-driven clinical trials. However, high assay-development and validation costs, complex regulatory pathways, reimbursement limitations, data-interpretation complexity, and uneven availability of advanced molecular testing infrastructure across regions are expected to restrain market growth to some extent.
“Assays, kits, reagents, and consumables accounted for the largest share of the cancer tumor profiling market, by offering, in 2025.”
Based on offering, the cancer tumor profiling market is segmented into products and services. Products include instruments and systems; and assays, kits, reagents, and consumables. Services include clinical tumor profiling testing services and biopharmaceutical, clinical-trial, and companion diagnostic services. In 2025, assays, kits, reagents, and consumables accounted for the largest share due to their recurring use across tissue and blood-based profiling workflows. Sequencing reagents, PCR consumables, antibodies, probes, sample-preparation kits, and other assay components are required for each patient test, creating sustained pull-through revenue. Their compatibility with high-throughput platforms and expanding use in diagnosis, molecular characterization, treatment selection, and clinical research further support the leading position of this segment.“Next-generation sequencing accounted for the largest share of the cancer tumor profiling market, by technology, in 2025.”
Based on technology, the global cancer tumor profiling market is segmented into next-generation sequencing; polymerase chain reaction, including qPCR, RT-PCR, and digital PCR; immunohistochemistry; in situ hybridization, including FISH, CISH, and SISH; and other tumor profiling technologies. In 2025, next-generation sequencing accounted for the largest share because of its ability to analyze multiple genes and genomic alterations simultaneously, detect rare and co-occurring biomarkers, and support comprehensive genomic profiling from tissue and blood samples. Increasing use of broad oncology panels, companion diagnostic assays, and liquid-biopsy workflows, together with growing demand for scalable molecular profiling in clinical trials, is expected to reinforce the segment’s leading position during the forecast period.“The Asia Pacific region is projected to grow at the highest CAGR in the cancer tumor profiling market from 2026 to 2031.”
The cancer tumor profiling market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, Asia Pacific is projected to register the highest CAGR due to rising cancer incidence, expanding oncology infrastructure, increasing investment in molecular diagnostics, and growing adoption of precision-medicine approaches. Growth is further supported by improving access to NGS and liquid-biopsy testing, expansion of pharmaceutical clinical trials, establishment of regional genomic laboratories, and the increasing presence of global and domestic diagnostics companies across China, Japan, India, South Korea, Australia, and Southeast Asia.List of Companies Profiled in the Report
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- Guardant Health, Inc.
- Tempus AI, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Laboratory Corporation of America Holdings (Labcorp)
- Abbott Laboratories
- Natera, Inc.
- NeoGenomics, Inc.
- Myriad Genetics, Inc.
- Agilent Technologies, Inc.
- Quest Diagnostics Incorporated
- Caris Life Sciences, Inc.
- Danaher Corporation
Research Coverage
This research report categorizes the cancer tumor profiling market by offering, technology, sample type, application, cancer type, end user, and region. The report provides detailed information on major market factors, including drivers, restraints, opportunities, and challenges. It analyzes leading industry participants and provides insights into their business overviews, product and service portfolios, technology capabilities, market positions, and key strategies, including product launches and approvals, partnerships, collaborations, agreements, acquisitions, expansions, and other recent developments. The report also covers regulatory trends, reimbursement considerations, precision-oncology adoption, biomarker-testing practices, and emerging technologies such as liquid biopsy, minimal residual disease testing, AI-enabled interpretation, spatial biology, and multi-omics. In addition, it evaluates established companies and emerging participants across the global cancer tumor profiling ecosystem.Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing close approximations of revenue for the overall cancer tumor profiling market and its subsegments. It will help stakeholders understand the competitive landscape, identify high-growth opportunities, assess technology and regional trends, and formulate effective product, partnership, investment, and go-to-market strategies. The report also provides an integrated view of the market pulse, covering key drivers, restraints, opportunities, and challenges.The report provides insights into the following points
- Analysis of key drivers, including increasing adoption of precision oncology and targeted therapies, expansion of NGS-based comprehensive genomic profiling, rising use of liquid biopsy, growing cancer incidence, and increasing pharmaceutical-diagnostic collaborations. The report also examines restraints such as high development and validation costs, reimbursement limitations, and data-interpretation complexity, as well as challenges related to regulatory requirements, standardization, and limited testing infrastructure in emerging markets.
- Product Development/Innovation: Detailed insights into newly launched and pipeline tumor profiling assays, sequencing platforms, pathology solutions, liquid-biopsy tests, companion diagnostics, minimal residual disease solutions, AI-enabled interpretation tools, and integrated molecular testing workflows.
- Market Development: Comprehensive information on attractive markets and growth opportunities across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, including country-level adoption patterns and regional expansion strategies.
- Market Diversification: Exhaustive information on product and service portfolios, technology developments, regulatory approvals, pharmaceutical partnerships, clinical-trial collaborations, acquisitions, laboratory expansions, and investments in the cancer tumor profiling market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, technology capabilities, clinical testing footprints, and service offerings of leading players, including F. Hoffmann-La Roche AG, Guardant Health, Inc., Illumina, Inc., Tempus AI, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Laboratory Corporation of America Holdings, Natera, Inc., NeoGenomics, Inc., Myriad Genetics, Inc., Agilent Technologies, Inc., Quest Diagnostics Incorporated, Caris Life Sciences, Inc., Abbott Laboratories, and Danaher Corporation.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 CANCER/TUMOR PROFILING MARKET OVERVIEW
3.2 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2026 VS. 2031
3.3 CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2026 VS. 2031
3.4 CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2026 VS. 2031
3.5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.6 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2026 VS. 2031
3.7 CANCER/TUMOR PROFILING MARKET, BY APPLICATION TYPE, 2026 VS. 2031
3.8 CANCER/TUMOR PROFILING MARKET, BY CLINICAL APPLICATION TYPE, 2026 VS. 2031
3.9 CANCER/TUMOR PROFILING MARKET, BY RESEARCH AND DRUG DEVELOPMENT APPLICATION, 2026 VS. 2031
3.10 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2026 VS. 2031
3.11 CANCER/TUMOR PROFILING MARKET, BY SOLID TUMOR TYPE, 2026 VS. 2031
3.12 CANCER/TUMOR PROFILING MARKET, BY LIQUID TUMOR, 2026 VS. 2031
3.13 CANCER/TUMOR PROFILING MARKET, BY END USER, 2026 VS. 2031
3.14 CANCER/TUMOR PROFILING MARKET, BY HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS, 2026 VS. 2031
3.15 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing adoption of precision oncology and targeted therapies
4.2.1.2 Rising adoption of comprehensive genomic profiling and NGS-based testing
4.2.1.3 Increasing cancer incidence and demand for molecular characterization
4.2.2 RESTRAINTS
4.2.2.1 High development, clinical validation, and regulatory approval costs
4.2.3 OPPORTUNITIES
4.2.3.1 Expansion of liquid biopsy and minimally invasive tumor profiling
4.2.3.2 AI-driven biomarker interpretation and digital pathology integration
4.2.4 CHALLENGES
4.2.4.1 Regulatory complexity associated with multi-analyte tumor profiling tests
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN CANCER/TUMOR PROFILING MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL CANCER/TUMOR PROFILING INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 CANCER/TUMOR PROFILING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFFS ON COMPANION DIAGNOSTICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Hospitals, Cancer Centers, and Oncology Clinics
5.11.5.2 Independent and Specialty Reference Laboratories
5.11.5.3 Pharmaceutical and Biotechnology Companies
5.11.5.4 Other end user
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 HIGH-SENSITIVITY LIQUID BIOPSY AND ERROR-CORRECTED SEQUENCING
6.1.2 SPATIAL, SINGLE-CELL, AND MULTIPLEX TISSUE PROFILING
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 AI-ENABLED BIOINFORMATICS AND CLINICAL DECISION SUPPORT
6.2.2 DIGITAL PATHOLOGY AND IMAGE ANALYSIS
6.3 ADJACENT TECHNOLOGIES
6.3.1 MOLECULAR IMAGING AND RADIOMICS
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON CANCER/TUMOR PROFILING MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES & MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY ANALYSIS
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 UK
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.3 Asia Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.5 Middle East
7.1.1.5.1 Africa
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
7.2.1.1 Eco-friendly initiatives
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
9 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 INSTRUMENTS AND SYSTEMS
9.2.1.1 Decentralized molecular testing and pressure to cut turnaround time to drive instrument demand
9.2.2 ASSAYS, KITS, REAGENTS, AND CONSUMABLES
9.2.2.1 Recurring-use model to link procedure volume directly to revenue
9.3 SERVICES
9.3.1 CLINICAL TUMOR PROFILING TESTING SERVICES
9.3.1.1 Rising clinical oncology tests and high selling prices to drive services growth
9.3.2 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES
9.3.2.1 Expanding oncology drug development to require broader biomarker adoption
10 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE
10.1 INTRODUCTION
10.2 TISSUE SAMPLES
10.2.1 TISSUE BIOPSY
10.3 BLOOD SAMPLES
10.3.1 LIQUID BIOPSY
10.4 BONE MARROW
10.4.1 RESEARCH AND CLINICAL-TRIAL SPECIMENS
10.5 OTHER SAMPLE TYPES
11 CANCER/TUMOR PROFILING MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL APPLICATIONS
11.2.1 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT
11.2.1.1 Integration of multi-omic biomarkers to redefine tumor diagnosis and classification
11.2.2 TREATMENT SELECTION AND COMPANION DIAGNOSTICS
11.2.2.1 Expanding targeted-therapy pipelines and pharma–diagnostic partnerships to drive companion diagnostics
11.2.3 TREATMENT-RESPONSE AND RESISTANCE MONITORING
11.2.3.1 Growing on-therapy profiling to monitor response and emerging resistance
11.2.4 RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION
11.2.4.1 Rising molecular residual disease testing to detect recurrence early
11.3 RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS
11.3.1 BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY
11.3.1.1 Wider use of whole-exome, transcriptome, and proteomic profiling to accelerate drug discovery
11.3.2 PRECLINICAL DEVELOPMENT AND VALIDATION
11.3.2.1 Molecular profiling of preclinical models to validate targets and characterize resistance
11.3.3 CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT
11.3.3.1 Growing number of oncology clinical trials to embed biomarker profiling
12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE
12.1 INTRODUCTION
12.2 SOLID TUMORS
12.2.1 LUNG CANCER
12.2.1.1 Broad actionable biomarkers to drive high molecular testing in lung cancer
12.2.2 BREAST CANCER
12.2.2.1 High incidence and complex molecular classification to expand breast cancer profiling
12.2.3 COLORECTAL CANCER
12.2.3.1 Established biomarkers and emerging MRD testing to expand colorectal cancer profiling
12.2.4 PROSTATE CANCER
12.2.4.1 Growing HRR-targeted therapies to broaden profiling in metastatic prostate cancer
12.2.5 GYNECOLOGIC CANCERS
12.2.5.1 HRD/BRCA testing and endometrial molecular stratification to drive gynecologic profiling
12.2.6 MELANOMA
12.2.6.1 BRAF testing and immunotherapy biomarkers to sustain melanoma profiling
12.2.7 BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS
12.2.7.1 Molecular criteria in WHO definitions to make profiling essential for CNS tumors
12.2.8 HEAD AND NECK CANCERS
12.2.8.1 Rising immunotherapy use and PD-L1 testing to expand head and neck cancer profiling
12.2.9 OTHER SOLID TUMORS
12.3 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES
12.3.1 LEUKEMIA
12.3.1.1 Routine molecular diagnosis and frequent MRD monitoring to drive leukemia profiling
12.3.2 LYMPHOMAS
12.3.2.1 Complex classification and growing genomic testing to broaden lymphoma profiling
12.3.3 MULTIPLE MYELOMA AND OTHER LIQUID TUMORS
12.3.3.1 NGS and sensitive MRD assays to create repeat testing in multiple myeloma
13 CANCER/TUMOR PROFILING MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS
13.2.1 MULTISPECIALTY HOSPITALS
13.2.1.1 Growing integration of biomarker testing to embed profiling in hospital oncology pathways
13.2.2 DEDICATED CANCER HOSPITALS AND CANCER CENTERS
13.2.2.1 High oncology volumes and research programs to drive profiling at cancer centers
13.3 INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES
13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.5 CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES
13.6 OTHER END USERS
14 CANCER/TUMOR PROFILING MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Advanced clinical genomics infrastructure and broad regulatory approvals to augment market growth
14.2.2 CANADA
14.2.2.1 Public funding of molecular profiling and expansion of national genomics capabilities to support growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Strong molecular tumor board networks and multi-omic precision oncology infrastructure to drive adoption
14.3.2 UK
14.3.2.1 NHS-funded genomic testing and centralized genomic laboratory network to support market maturity
14.3.3 FRANCE
14.3.3.1 National genomic medicine infrastructure to accelerate tumor profiling
14.3.4 ITALY
14.3.4.1 Public funding for NGS and genomic testing to support precision-oncology expansion
14.3.5 SPAIN
14.3.5.1 National genomic test catalog and strong oncology research network to support market growth
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Large cancer burden and formalization of clinical NGS standards to drive market expansion
14.4.2 JAPAN
14.4.2.1 National insurance coverage and C-CAT infrastructure to support broad CGP adoption
14.4.3 INDIA
14.4.3.1 Rising cancer burden and expansion of indigenous genomic infrastructure to support high growth
14.4.4 SOUTH KOREA
14.4.4.1 Government-backed NGS precision-oncology programs to accelerate clinical adoption
14.4.5 AUSTRALIA
14.4.5.1 National genomics framework and government investments to strengthen precision oncology
14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 National genomics program and local tumor atlas development to accelerate precision oncology
14.5.2 MEXICO
14.5.2.1 Expansion of national cancer genotyping infrastructure to support market development
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
14.7 GCC COUNTRIES
14.7.1 GOVERNMENT-LED GENOMICS AND PRECISION-MEDICINE INVESTMENTS TO CREATE HIGH-GROWTH OPPORTUNITIES
14.8 REST OF MIDDLE EAST & AFRICA
14.8.1 LARGE UNMET NEED FOR BIOMARKER TESTING AND GRADUAL BUILD-OUT OF MOLECULAR ONCOLOGY CAPACITY
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER/TUMOR PROFILING MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Regional footprint
15.5.5.3 Product & service footprint
15.5.5.4 Technology footprint
15.5.5.5 Sample Type footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
15.9.4 OTHER DEVELOPMENTS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 F. HOFFMANN-LA ROCHE LTD.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ILLUMINA, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.3.3 Other developments
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 THERMO FISHER SCIENTIFIC INC.
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 QIAGEN
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches & approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Key strengths
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 GUARDANT HEALTH
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches & approvals
16.1.5.4 MnM view
16.1.5.4.1 Key strengths
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 LABCORP
16.1.6.1 Business overview
16.1.6.2 Product & Services offered
16.1.6.3 Recent developments
16.1.6.3.1 Service Launches, and Approvals
16.1.6.3.2 Deals
16.1.6.3.3 Expansions
16.1.7 ABBOTT
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product approvals
16.1.7.3.2 Deals
16.1.8 TEMPUS AI, INC.
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product approvals
16.1.8.3.2 Deals
16.1.8.3.3 Other developments
16.1.9 NATERA, INC.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches & Approvals
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.9.3.4 Other developments
16.1.10 NEOGENOMICS LABORATORIES, INC
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches & approvals
16.1.10.3.2 Deals
16.1.10.3.3 Expansions
16.1.11 MYRIAD GENETICS, INC.
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches & approvals
16.1.11.3.2 Deals
16.1.12 AGILENT TECHNOLOGIES, INC
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches & approvals
16.1.12.3.2 Deals
16.1.12.3.3 Expansions
16.1.13 QUEST DIAGNOSTICS
16.1.13.1 Business overview
16.1.13.2 Products/Services/Solutions offered
16.1.13.3 Recent developments
16.1.13.3.1 Product/Services launches & approvals
16.1.13.3.2 Deals
16.1.14 CARIS LIFE SCIENCES, INC.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches & approvals
16.1.14.3.2 Deals
16.1.15 DANAHER
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Deals
16.2 OTHER PLAYERS
16.2.1 INSIGHT MOLECULAR DIAGNOSTICS, INC (IMDX) (ONCOCYTE CORPORATION)
16.2.2 ONCODNA SA
16.2.3 MOLECULAR HEALTH GMBH
16.2.4 ALMAC DIAGNOSTIC SERVICES (THE ALMAC GROUP)
16.2.5 INVIVOSCRIBE, INC.
16.2.6 ACT GENOMICS CO., LTD.
16.2.7 LUCENCE HEALTH INC
16.2.8 GC GENOME CORPORATION
16.2.9 MEDGENOME LABS LTD.
16.2.10 MGI TECH CO., LTD.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 List of secondary sources
17.1.1.2 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 List of primary sources
17.1.2.2 Key data from primary sources
17.1.2.3 Key industry insights
17.1.2.4 Breakdown of primary interviews
17.2 MARKET SIZE ESTIMATION
17.2.1 TOTAL MARKET SIZE: CANCER/TUMOR PROFILING MARKET
17.2.2 BOTTOM-UP APPROACH
17.2.2.1 Approach 1: Revenue estimation of key players
17.2.2.2 Approach 2: Study of annual reports and investor presentations
17.2.2.3 Approach 3: Primary interviews
17.2.2.4 Growth forecast
17.2.3 TOP-DOWN APPROACH
17.3 DATA TRIANGULATION
17.4 RESEARCH ASSUMPTIONS
17.4.1 STUDY-RELATED ASSUMPTIONS
17.4.2 GROWTH RATE ASSUMPTIONS
17.5 RESEARCH LIMITATIONS
17.6 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 CANCER/TUMOR PROFILING MARKET OVERVIEW
3.2 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2026 VS. 2031
3.3 CANCER/TUMOR PROFILING MARKET, BY PRODUCT TYPE, 2026 VS. 2031
3.4 CANCER/TUMOR PROFILING MARKET, BY SERVICE TYPE, 2026 VS. 2031
3.5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.6 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2026 VS. 2031
3.7 CANCER/TUMOR PROFILING MARKET, BY APPLICATION TYPE, 2026 VS. 2031
3.8 CANCER/TUMOR PROFILING MARKET, BY CLINICAL APPLICATION TYPE, 2026 VS. 2031
3.9 CANCER/TUMOR PROFILING MARKET, BY RESEARCH AND DRUG DEVELOPMENT APPLICATION, 2026 VS. 2031
3.10 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2026 VS. 2031
3.11 CANCER/TUMOR PROFILING MARKET, BY SOLID TUMOR TYPE, 2026 VS. 2031
3.12 CANCER/TUMOR PROFILING MARKET, BY LIQUID TUMOR, 2026 VS. 2031
3.13 CANCER/TUMOR PROFILING MARKET, BY END USER, 2026 VS. 2031
3.14 CANCER/TUMOR PROFILING MARKET, BY HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS, 2026 VS. 2031
3.15 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Increasing adoption of precision oncology and targeted therapies
4.2.1.2 Rising adoption of comprehensive genomic profiling and NGS-based testing
4.2.1.3 Increasing cancer incidence and demand for molecular characterization
4.2.2 RESTRAINTS
4.2.2.1 High development, clinical validation, and regulatory approval costs
4.2.3 OPPORTUNITIES
4.2.3.1 Expansion of liquid biopsy and minimally invasive tumor profiling
4.2.3.2 AI-driven biomarker interpretation and digital pathology integration
4.2.4 CHALLENGES
4.2.4.1 Regulatory complexity associated with multi-analyte tumor profiling tests
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN CANCER/TUMOR PROFILING MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL CANCER/TUMOR PROFILING INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 CANCER/TUMOR PROFILING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF 2025 US TARIFFS ON COMPANION DIAGNOSTICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Hospitals, Cancer Centers, and Oncology Clinics
5.11.5.2 Independent and Specialty Reference Laboratories
5.11.5.3 Pharmaceutical and Biotechnology Companies
5.11.5.4 Other end user
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 HIGH-SENSITIVITY LIQUID BIOPSY AND ERROR-CORRECTED SEQUENCING
6.1.2 SPATIAL, SINGLE-CELL, AND MULTIPLEX TISSUE PROFILING
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 AI-ENABLED BIOINFORMATICS AND CLINICAL DECISION SUPPORT
6.2.2 DIGITAL PATHOLOGY AND IMAGE ANALYSIS
6.3 ADJACENT TECHNOLOGIES
6.3.1 MOLECULAR IMAGING AND RADIOMICS
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON CANCER/TUMOR PROFILING MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES & MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 SUSTAINABILITY & REGULATORY LANDSCAPE
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY ANALYSIS
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 UK
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.3 Asia Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.5 Middle East
7.1.1.5.1 Africa
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
7.2.1.1 Eco-friendly initiatives
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.5.1 REVENUE POTENTIAL
8.5.2 COST DYNAMICS
9 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 INSTRUMENTS AND SYSTEMS
9.2.1.1 Decentralized molecular testing and pressure to cut turnaround time to drive instrument demand
9.2.2 ASSAYS, KITS, REAGENTS, AND CONSUMABLES
9.2.2.1 Recurring-use model to link procedure volume directly to revenue
9.3 SERVICES
9.3.1 CLINICAL TUMOR PROFILING TESTING SERVICES
9.3.1.1 Rising clinical oncology tests and high selling prices to drive services growth
9.3.2 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES
9.3.2.1 Expanding oncology drug development to require broader biomarker adoption
10 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE
10.1 INTRODUCTION
10.2 TISSUE SAMPLES
10.2.1 TISSUE BIOPSY
10.3 BLOOD SAMPLES
10.3.1 LIQUID BIOPSY
10.4 BONE MARROW
10.4.1 RESEARCH AND CLINICAL-TRIAL SPECIMENS
10.5 OTHER SAMPLE TYPES
11 CANCER/TUMOR PROFILING MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 CLINICAL APPLICATIONS
11.2.1 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT
11.2.1.1 Integration of multi-omic biomarkers to redefine tumor diagnosis and classification
11.2.2 TREATMENT SELECTION AND COMPANION DIAGNOSTICS
11.2.2.1 Expanding targeted-therapy pipelines and pharma–diagnostic partnerships to drive companion diagnostics
11.2.3 TREATMENT-RESPONSE AND RESISTANCE MONITORING
11.2.3.1 Growing on-therapy profiling to monitor response and emerging resistance
11.2.4 RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION
11.2.4.1 Rising molecular residual disease testing to detect recurrence early
11.3 RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS
11.3.1 BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY
11.3.1.1 Wider use of whole-exome, transcriptome, and proteomic profiling to accelerate drug discovery
11.3.2 PRECLINICAL DEVELOPMENT AND VALIDATION
11.3.2.1 Molecular profiling of preclinical models to validate targets and characterize resistance
11.3.3 CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT
11.3.3.1 Growing number of oncology clinical trials to embed biomarker profiling
12 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE
12.1 INTRODUCTION
12.2 SOLID TUMORS
12.2.1 LUNG CANCER
12.2.1.1 Broad actionable biomarkers to drive high molecular testing in lung cancer
12.2.2 BREAST CANCER
12.2.2.1 High incidence and complex molecular classification to expand breast cancer profiling
12.2.3 COLORECTAL CANCER
12.2.3.1 Established biomarkers and emerging MRD testing to expand colorectal cancer profiling
12.2.4 PROSTATE CANCER
12.2.4.1 Growing HRR-targeted therapies to broaden profiling in metastatic prostate cancer
12.2.5 GYNECOLOGIC CANCERS
12.2.5.1 HRD/BRCA testing and endometrial molecular stratification to drive gynecologic profiling
12.2.6 MELANOMA
12.2.6.1 BRAF testing and immunotherapy biomarkers to sustain melanoma profiling
12.2.7 BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS
12.2.7.1 Molecular criteria in WHO definitions to make profiling essential for CNS tumors
12.2.8 HEAD AND NECK CANCERS
12.2.8.1 Rising immunotherapy use and PD-L1 testing to expand head and neck cancer profiling
12.2.9 OTHER SOLID TUMORS
12.3 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES
12.3.1 LEUKEMIA
12.3.1.1 Routine molecular diagnosis and frequent MRD monitoring to drive leukemia profiling
12.3.2 LYMPHOMAS
12.3.2.1 Complex classification and growing genomic testing to broaden lymphoma profiling
12.3.3 MULTIPLE MYELOMA AND OTHER LIQUID TUMORS
12.3.3.1 NGS and sensitive MRD assays to create repeat testing in multiple myeloma
13 CANCER/TUMOR PROFILING MARKET, BY END USER
13.1 INTRODUCTION
13.2 HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS
13.2.1 MULTISPECIALTY HOSPITALS
13.2.1.1 Growing integration of biomarker testing to embed profiling in hospital oncology pathways
13.2.2 DEDICATED CANCER HOSPITALS AND CANCER CENTERS
13.2.2.1 High oncology volumes and research programs to drive profiling at cancer centers
13.3 INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES
13.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.5 CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES
13.6 OTHER END USERS
14 CANCER/TUMOR PROFILING MARKET, BY REGION
14.1 INTRODUCTION
14.2 NORTH AMERICA
14.2.1 US
14.2.1.1 Advanced clinical genomics infrastructure and broad regulatory approvals to augment market growth
14.2.2 CANADA
14.2.2.1 Public funding of molecular profiling and expansion of national genomics capabilities to support growth
14.3 EUROPE
14.3.1 GERMANY
14.3.1.1 Strong molecular tumor board networks and multi-omic precision oncology infrastructure to drive adoption
14.3.2 UK
14.3.2.1 NHS-funded genomic testing and centralized genomic laboratory network to support market maturity
14.3.3 FRANCE
14.3.3.1 National genomic medicine infrastructure to accelerate tumor profiling
14.3.4 ITALY
14.3.4.1 Public funding for NGS and genomic testing to support precision-oncology expansion
14.3.5 SPAIN
14.3.5.1 National genomic test catalog and strong oncology research network to support market growth
14.3.6 REST OF EUROPE
14.4 ASIA PACIFIC
14.4.1 CHINA
14.4.1.1 Large cancer burden and formalization of clinical NGS standards to drive market expansion
14.4.2 JAPAN
14.4.2.1 National insurance coverage and C-CAT infrastructure to support broad CGP adoption
14.4.3 INDIA
14.4.3.1 Rising cancer burden and expansion of indigenous genomic infrastructure to support high growth
14.4.4 SOUTH KOREA
14.4.4.1 Government-backed NGS precision-oncology programs to accelerate clinical adoption
14.4.5 AUSTRALIA
14.4.5.1 National genomics framework and government investments to strengthen precision oncology
14.4.6 REST OF ASIA PACIFIC
14.5 LATIN AMERICA
14.5.1 BRAZIL
14.5.1.1 National genomics program and local tumor atlas development to accelerate precision oncology
14.5.2 MEXICO
14.5.2.1 Expansion of national cancer genotyping infrastructure to support market development
14.5.3 REST OF LATIN AMERICA
14.6 MIDDLE EAST & AFRICA
14.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
14.7 GCC COUNTRIES
14.7.1 GOVERNMENT-LED GENOMICS AND PRECISION-MEDICINE INVESTMENTS TO CREATE HIGH-GROWTH OPPORTUNITIES
14.8 REST OF MIDDLE EAST & AFRICA
14.8.1 LARGE UNMET NEED FOR BIOMARKER TESTING AND GRADUAL BUILD-OUT OF MOLECULAR ONCOLOGY CAPACITY
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CANCER/TUMOR PROFILING MARKET
15.3 REVENUE ANALYSIS, 2023–2025
15.4 MARKET SHARE ANALYSIS, 2025
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
15.5.1 STARS
15.5.2 EMERGING LEADERS
15.5.3 PERVASIVE PLAYERS
15.5.4 PARTICIPANTS
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
15.5.5.1 Company footprint
15.5.5.2 Regional footprint
15.5.5.3 Product & service footprint
15.5.5.4 Technology footprint
15.5.5.5 Sample Type footprint
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.1 PROGRESSIVE COMPANIES
15.6.2 RESPONSIVE COMPANIES
15.6.3 DYNAMIC COMPANIES
15.6.4 STARTING BLOCKS
15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
15.6.5.1 Detailed list of key startups/SMEs
15.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
15.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
15.7 COMPANY VALUATION & FINANCIAL METRICS
15.7.1 FINANCIAL METRICS
15.7.2 COMPANY VALUATION
15.8 BRAND/PRODUCT COMPARISON
15.9 COMPETITIVE SCENARIO
15.9.1 PRODUCT LAUNCHES & APPROVALS
15.9.2 DEALS
15.9.3 EXPANSIONS
15.9.4 OTHER DEVELOPMENTS
16 COMPANY PROFILES
16.1 KEY PLAYERS
16.1.1 F. HOFFMANN-LA ROCHE LTD.
16.1.1.1 Business overview
16.1.1.2 Products offered
16.1.1.3 Recent developments
16.1.1.3.1 Product launches & approvals
16.1.1.3.2 Deals
16.1.1.3.3 Expansions
16.1.1.4 MnM view
16.1.1.4.1 Key strengths
16.1.1.4.2 Strategic choices
16.1.1.4.3 Weaknesses & competitive threats
16.1.2 ILLUMINA, INC.
16.1.2.1 Business overview
16.1.2.2 Products offered
16.1.2.3 Recent developments
16.1.2.3.1 Product launches & approvals
16.1.2.3.2 Deals
16.1.2.3.3 Other developments
16.1.2.4 MnM view
16.1.2.4.1 Key strengths
16.1.2.4.2 Strategic choices
16.1.2.4.3 Weaknesses & competitive threats
16.1.3 THERMO FISHER SCIENTIFIC INC.
16.1.3.1 Business overview
16.1.3.2 Products offered
16.1.3.3 Recent developments
16.1.3.3.1 Product launches
16.1.3.3.2 Deals
16.1.3.4 MnM view
16.1.3.4.1 Key strengths
16.1.3.4.2 Strategic choices
16.1.3.4.3 Weaknesses & competitive threats
16.1.4 QIAGEN
16.1.4.1 Business overview
16.1.4.2 Products offered
16.1.4.3 Recent developments
16.1.4.3.1 Product launches & approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.4 MnM view
16.1.4.4.1 Key strengths
16.1.4.4.2 Strategic choices
16.1.4.4.3 Weaknesses & competitive threats
16.1.5 GUARDANT HEALTH
16.1.5.1 Business overview
16.1.5.2 Products offered
16.1.5.3 Recent developments
16.1.5.3.1 Product launches & approvals
16.1.5.4 MnM view
16.1.5.4.1 Key strengths
16.1.5.4.2 Strategic choices
16.1.5.4.3 Weaknesses & competitive threats
16.1.6 LABCORP
16.1.6.1 Business overview
16.1.6.2 Product & Services offered
16.1.6.3 Recent developments
16.1.6.3.1 Service Launches, and Approvals
16.1.6.3.2 Deals
16.1.6.3.3 Expansions
16.1.7 ABBOTT
16.1.7.1 Business overview
16.1.7.2 Products offered
16.1.7.3 Recent developments
16.1.7.3.1 Product approvals
16.1.7.3.2 Deals
16.1.8 TEMPUS AI, INC.
16.1.8.1 Business overview
16.1.8.2 Products offered
16.1.8.3 Recent developments
16.1.8.3.1 Product approvals
16.1.8.3.2 Deals
16.1.8.3.3 Other developments
16.1.9 NATERA, INC.
16.1.9.1 Business overview
16.1.9.2 Products offered
16.1.9.3 Recent developments
16.1.9.3.1 Product launches & Approvals
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.9.3.4 Other developments
16.1.10 NEOGENOMICS LABORATORIES, INC
16.1.10.1 Business overview
16.1.10.2 Products offered
16.1.10.3 Recent developments
16.1.10.3.1 Product launches & approvals
16.1.10.3.2 Deals
16.1.10.3.3 Expansions
16.1.11 MYRIAD GENETICS, INC.
16.1.11.1 Business overview
16.1.11.2 Products offered
16.1.11.3 Recent developments
16.1.11.3.1 Product launches & approvals
16.1.11.3.2 Deals
16.1.12 AGILENT TECHNOLOGIES, INC
16.1.12.1 Business overview
16.1.12.2 Products offered
16.1.12.3 Recent developments
16.1.12.3.1 Product launches & approvals
16.1.12.3.2 Deals
16.1.12.3.3 Expansions
16.1.13 QUEST DIAGNOSTICS
16.1.13.1 Business overview
16.1.13.2 Products/Services/Solutions offered
16.1.13.3 Recent developments
16.1.13.3.1 Product/Services launches & approvals
16.1.13.3.2 Deals
16.1.14 CARIS LIFE SCIENCES, INC.
16.1.14.1 Business overview
16.1.14.2 Products offered
16.1.14.3 Recent developments
16.1.14.3.1 Product launches & approvals
16.1.14.3.2 Deals
16.1.15 DANAHER
16.1.15.1 Business overview
16.1.15.2 Products offered
16.1.15.3 Recent developments
16.1.15.3.1 Deals
16.2 OTHER PLAYERS
16.2.1 INSIGHT MOLECULAR DIAGNOSTICS, INC (IMDX) (ONCOCYTE CORPORATION)
16.2.2 ONCODNA SA
16.2.3 MOLECULAR HEALTH GMBH
16.2.4 ALMAC DIAGNOSTIC SERVICES (THE ALMAC GROUP)
16.2.5 INVIVOSCRIBE, INC.
16.2.6 ACT GENOMICS CO., LTD.
16.2.7 LUCENCE HEALTH INC
16.2.8 GC GENOME CORPORATION
16.2.9 MEDGENOME LABS LTD.
16.2.10 MGI TECH CO., LTD.
17 RESEARCH METHODOLOGY
17.1 RESEARCH DATA
17.1.1 SECONDARY DATA
17.1.1.1 List of secondary sources
17.1.1.2 Key data from secondary sources
17.1.2 PRIMARY DATA
17.1.2.1 List of primary sources
17.1.2.2 Key data from primary sources
17.1.2.3 Key industry insights
17.1.2.4 Breakdown of primary interviews
17.2 MARKET SIZE ESTIMATION
17.2.1 TOTAL MARKET SIZE: CANCER/TUMOR PROFILING MARKET
17.2.2 BOTTOM-UP APPROACH
17.2.2.1 Approach 1: Revenue estimation of key players
17.2.2.2 Approach 2: Study of annual reports and investor presentations
17.2.2.3 Approach 3: Primary interviews
17.2.2.4 Growth forecast
17.2.3 TOP-DOWN APPROACH
17.3 DATA TRIANGULATION
17.4 RESEARCH ASSUMPTIONS
17.4.1 STUDY-RELATED ASSUMPTIONS
17.4.2 GROWTH RATE ASSUMPTIONS
17.5 RESEARCH LIMITATIONS
17.6 RISK ASSESSMENT
18 APPENDIX
18.1 DISCUSSION GUIDE
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3 CUSTOMIZATION OPTIONS
18.4 RELATED REPORTS
18.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 INCLUSIONS & EXCLUSIONS
TABLE 2 CANCER/TUMOR PROFILING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2023–2030
TABLE 4 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 5 EUROPE: MACROECONOMIC INDICATORS
TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 9 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY KEY PLAYER, 2024–2026 (USD)
TABLE 10 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 13 CANCER/TUMOR PROFILING MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN CANCER/TUMOR PROFILING MARKET
TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 27 CANCER/TUMOR PROFILING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION)
TABLE 29 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 35 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 36 CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 EUROPE: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 40 LATIN AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 42 CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 CANCER/TUMOR PROFILING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 NORTH AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 EUROPE: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 ASIA PACIFIC: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 52 LATIN AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 54 CANCER/TUMOR PROFILING SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 55 CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 EUROPE: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 58 ASIA PACIFIC: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 59 LATIN AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 61 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 NORTH AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 EUROPE: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 64 ASIA PACIFIC: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 65 LATIN AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 67 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 68 CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 EUROPE: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 72 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 74 CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 EUROPE: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 77 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 78 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 79 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 80 CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 84 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 86 CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 90 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 92 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 93 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 97 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 98 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 99 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION)
TABLE 100 CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 105 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 106 CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 109 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 110 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 112 CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 115 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 118 CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 121 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 122 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 124 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 127 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 128 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 129 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 130 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION)
TABLE 131 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 132 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 EUROPE: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 134 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 135 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 137 CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 141 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 143 CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 149 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024–2031 (USD MILLION)
TABLE 150 SOLID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 154 LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 155 MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 156 SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION)
TABLE 157 LUNG CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 NORTH AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 EUROPE: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 161 LATIN AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 163 BREAST CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 NORTH AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 EUROPE: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 166 ASIA PACIFIC: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 167 LATIN AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 169 COLORECTAL CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 170 NORTH AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 EUROPE: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 173 LATIN AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 174 MIDDLE EAST & AFRICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 175 PROSTATE CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 NORTH AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 EUROPE: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 178 ASIA PACIFIC: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 179 LATIN AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 180 MIDDLE EAST & AFRICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 181 GYNECOLOGIC CANCERS PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 182 NORTH AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 EUROPE: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 184 ASIA PACIFIC: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 185 LATIN AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 187 MELANOMA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 188 NORTH AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 190 ASIA PACIFIC: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 191 LATIN AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 193 BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 197 LATIN AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 199 HEAD AND NECK CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 204 MIDDLE EAST & AFRICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 205 OTHER SOLID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 NORTH AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 EUROPE: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 208 ASIA PACIFIC: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 209 LATIN AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 210 MIDDLE EAST & AFRICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 211 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 NORTH AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 EUROPE: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 215 LATIN AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 216 MIDDLE EAST & AFRICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 217 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218 LEUKEMIA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 219 NORTH AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 EUROPE: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 221 ASIA PACIFIC: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 222 LATIN AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 224 LYMPHOMA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 225 NORTH AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 EUROPE: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 227 ASIA PACIFIC: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 228 LATIN AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 230 MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 231 NORTH AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 EUROPE: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 234 LATIN AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 235 MIDDLE EAST & AFRICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 236 CANCER/TUMOR PROFILING MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 237 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 238 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 241 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 242 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 243 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 244 CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 250 CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 251 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 EUROPE: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 253 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 254 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 255 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 256 CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 257 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 EUROPE: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 259 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 260 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 261 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 262 CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 263 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 265 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 266 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 267 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 268 CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 269 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 EUROPE: CANCER/TUMOR PROFILING MARKET CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 271 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 272 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 273 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 274 CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 275 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 277 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 278 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 280 CANCER/TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 282 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION)
TABLE 1 INCLUSIONS & EXCLUSIONS
TABLE 2 CANCER/TUMOR PROFILING MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2023–2030
TABLE 4 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 5 EUROPE: MACROECONOMIC INDICATORS
TABLE 6 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 7 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 8 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 9 AVERAGE SELLING PRICE TREND OF CANCER/TUMOR PROFILING OFFERING, BY KEY PLAYER, 2024–2026 (USD)
TABLE 10 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 13 CANCER/TUMOR PROFILING MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN CANCER/TUMOR PROFILING MARKET
TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 27 CANCER/TUMOR PROFILING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28 CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION)
TABLE 29 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING PRODUCTS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 35 CANCER/TUMOR PROFILING PRODUCTS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 36 CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 NORTH AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 EUROPE: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 40 LATIN AMERICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING INSTRUMENTS AND SYSTEMS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 42 CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 43 NORTH AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44 EUROPE: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 ASIA PACIFIC: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 46 LATIN AMERICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING ASSAYS, KITS, REAGENTS, AND CONSUMABLES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 CANCER/TUMOR PROFILING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 49 NORTH AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 EUROPE: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 ASIA PACIFIC: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 52 LATIN AMERICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 54 CANCER/TUMOR PROFILING SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION)
TABLE 55 CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 56 NORTH AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 EUROPE: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 58 ASIA PACIFIC: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 59 LATIN AMERICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA: CLINICAL TUMOR PROFILING TESTING SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 61 BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62 NORTH AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 EUROPE: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 64 ASIA PACIFIC: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 65 LATIN AMERICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL, CLINICAL-TRIAL, AND COMPANION DIAGNOSTIC SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 67 CANCER/TUMOR PROFILING MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 68 CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 EUROPE: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 71 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 72 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN TISSUE SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 74 CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION)
TABLE 75 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 EUROPE: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 77 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 78 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 79 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BLOOD SAMPLES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 80 CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 84 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN BONE MARROWS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 86 CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION)
TABLE 87 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 EUROPE: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 89 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 90 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN OTHER SAMPLE TYPES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 92 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 93 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 97 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 98 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 99 CANCER/TUMOR PROFILING MARKET IN CLINICAL APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION)
TABLE 100 CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 103 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 104 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 105 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION, AND PROGNOSTIC/RISK ASSESSMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 106 CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 109 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 110 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT SELECTION AND COMPANION DIAGNOSTICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 112 CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY REGION, 2024–2031 (USD MILLION)
TABLE 113 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114 EUROPE: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 115 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 116 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 117 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR TREATMENT-RESPONSE AND RESISTANCE MONITORING, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 118 CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 119 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 121 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 122 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 123 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESIDUAL DISEASE, POST-TREATMENT SURVEILLANCE, AND RECURRENCE DETECTION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 124 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 125 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 EUROPE: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 127 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 128 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 129 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 130 CANCER/TUMOR PROFILING MARKET IN RESEARCH AND DRUG-DEVELOPMENT APPLICATIONS, BY APPLICATION TYPE, 2024–2031 (USD MILLION)
TABLE 131 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION)
TABLE 132 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 EUROPE: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 134 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 135 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR BIOMARKER, TARGET, AND EARLY DRUG DISCOVERY, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 137 CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 141 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 142 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PRECLINICAL DEVELOPMENT AND VALIDATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 143 CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY REGION, 2024–2031 (USD MILLION)
TABLE 144 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 146 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 147 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 148 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL TRIALS, PATIENT STRATIFICATION, AND ENROLLMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 149 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2024–2031 (USD MILLION)
TABLE 150 SOLID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 151 NORTH AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 EUROPE: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 153 ASIA PACIFIC: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 154 LATIN AMERICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 155 MIDDLE EAST & AFRICA: SOLID TUMOR PROFILING MARKET, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 156 SOLID TUMOR PROFILING MARKET, BY TUMOR TYPE, 2024–2031 (USD MILLION)
TABLE 157 LUNG CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 158 NORTH AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159 EUROPE: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 160 ASIA PACIFIC: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 161 LATIN AMERICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: LUNG CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 163 BREAST CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 NORTH AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 EUROPE: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 166 ASIA PACIFIC: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 167 LATIN AMERICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: BREAST CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 169 COLORECTAL CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 170 NORTH AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 171 EUROPE: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 172 ASIA PACIFIC: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 173 LATIN AMERICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 174 MIDDLE EAST & AFRICA: COLORECTAL CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 175 PROSTATE CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 176 NORTH AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 EUROPE: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 178 ASIA PACIFIC: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 179 LATIN AMERICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 180 MIDDLE EAST & AFRICA: PROSTATE CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 181 GYNECOLOGIC CANCERS PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 182 NORTH AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 EUROPE: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 184 ASIA PACIFIC: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 185 LATIN AMERICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 186 MIDDLE EAST & AFRICA: GYNECOLOGIC CANCERS PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 187 MELANOMA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 188 NORTH AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 190 ASIA PACIFIC: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 191 LATIN AMERICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: MELANOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 193 BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 194 NORTH AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 EUROPE: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 196 ASIA PACIFIC: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 197 LATIN AMERICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: BRAIN AND CENTRAL NERVOUS SYSTEM TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 199 HEAD AND NECK CANCER PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 NORTH AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EUROPE: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 202 ASIA PACIFIC: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 203 LATIN AMERICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 204 MIDDLE EAST & AFRICA: HEAD AND NECK CANCER PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 205 OTHER SOLID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 206 NORTH AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 EUROPE: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 208 ASIA PACIFIC: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 209 LATIN AMERICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 210 MIDDLE EAST & AFRICA: OTHER SOLID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 211 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 212 NORTH AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 EUROPE: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 214 ASIA PACIFIC: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 215 LATIN AMERICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 216 MIDDLE EAST & AFRICA: LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 217 LIQUID TUMOR/HEMATOLOGIC MALIGNANCIES PROFILING MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 218 LEUKEMIA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 219 NORTH AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 EUROPE: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 221 ASIA PACIFIC: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 222 LATIN AMERICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 223 MIDDLE EAST & AFRICA: LEUKEMIA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 224 LYMPHOMA PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 225 NORTH AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 EUROPE: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 227 ASIA PACIFIC: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 228 LATIN AMERICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: LYMPHOMA PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 230 MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 231 NORTH AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 EUROPE: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 234 LATIN AMERICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 235 MIDDLE EAST & AFRICA: MULTIPLE MYELOMA AND OTHER LIQUID TUMOR PROFILING MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 236 CANCER/TUMOR PROFILING MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 237 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 238 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 EUROPE: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 241 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 242 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 243 CANCER/TUMOR PROFILING MARKET FOR HOSPITALS, CANCER CENTERS, AND ONCOLOGY CLINICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 244 CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR MULTISPECIALTY HOSPITALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 250 CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 251 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 EUROPE: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 253 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 254 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 255 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR DEDICATED CANCER HOSPITALS AND CANCER CENTERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 256 CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 257 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 EUROPE: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 259 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 260 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 261 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR INDEPENDENT AND SPECIALTY REFERENCE LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 262 CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 263 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 EUROPE: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 265 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 266 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 267 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 268 CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 269 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 EUROPE: CANCER/TUMOR PROFILING MARKET CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 271 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 272 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 273 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CENTRAL LABORATORIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 274 CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 275 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 276 EUROPE: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 277 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 278 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 279 MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR OTHER END USERS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 280 CANCER/TUMOR PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 281 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 282 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 283 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY PRODUCT & SERVICE OFFERING, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 CANCER/TUMOR PROFILING MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 STUDY YEARS CONSIDERED
FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS
FIGURE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023–2025
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER/TUMOR PROFILING MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN CANCER/TUMOR PROFILING MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9 INCREASING ADOPTION OF PRECISION ONCOLOGY TO DRIVE MARKET
FIGURE 10 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 11 ASSAYS, KITS & REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 CLINICAL TUMOR PROFILING TESTING SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 NEXT GENERATION SEQUENCING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15 CLINICAL APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 16 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION AND PROGNOSTIC/RISK ASSESSMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 17 BIOMARKER, TARGET AND EARLY DRUG DISCOVERY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 18 SOLID TUMOR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 19 LUNG CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 20 LEUKEMIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 21 HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 22 DEDICATED CANCER HOSPITALS AND CANCER CENTERS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 24 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25 CANCER/TUMOR PROFILING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 26 CANCER/TUMOR PROFILING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 27 CANCER/ TUMOR PROFILING MARKET: VALUE CHAIN ANALYSIS
FIGURE 28 CANCER/TUMOR PROFILING MARKET: ECOSYSTEM ANALYSIS
FIGURE 29 CANCER/TUMOR PROFILING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES OF KEY PLAYERS IN THE CANCER/TUMOR PROFILING MARKET
FIGURE 31 PATENT ANALYSIS FOR CANCER/TUMOR PROFILING MARKET, JANUARY 2016–DECEMBER 2025
FIGURE 32 MARKET POTENTIAL OF AI IN CANCER/TUMOR PROFILING MARKET
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE OFFERING
FIGURE 34 KEY BUYING CRITERIA, BY PRODUCT & SERVICE OFFERING
FIGURE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 36 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023–2025 (USD MILLION)
FIGURE 38 CANCER/TUMOR PROFILING MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 40 CANCER/TUMOR PROFILING MARKET: COMPANY FOOTPRINT
FIGURE 41 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 42 EV/EBITDA OF KEY VENDORS
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 44 CANCER/TUMOR PROFILING MARKET: BRAND/PRODUCT COMPARISON FOR CANCER/TUMOR PROFILING
FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 50 LABCORP: COMPANY SNAPSHOT (2025)
FIGURE 51 ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 52 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 53 NATERA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 54 NEOGENOMICS LABORATORIES, INC: COMPANY SNAPSHOT (2025)
FIGURE 55 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 57 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025)
FIGURE 58 CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 59 DANAHER: COMPANY SNAPSHOT (2025)
FIGURE 60 RESEARCH DESIGN
FIGURE 61 KEY DATA FROM SECONDARY SOURCES
FIGURE 62 LIST OF PRIMARY SOURCES
FIGURE 63 KEY INDUSTRY INSIGHTS
FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 65 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
FIGURE 66 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031): IMPACT ON MARKET GROWTH AND CAGR
FIGURE 67 CAGR PROJECTIONS
FIGURE 68 TOP-DOWN APPROACH
FIGURE 69 DATA TRIANGULATION
FIGURE 70 PARAMETRIC ASSUMPTIONS
FIGURE 1 CANCER/TUMOR PROFILING MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 STUDY YEARS CONSIDERED
FIGURE 3 KEY INSIGHTS & MARKET HIGHLIGHTS
FIGURE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, 2024–2031
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023–2025
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF CANCER/TUMOR PROFILING MARKET
FIGURE 7 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN CANCER/TUMOR PROFILING MARKET, 2025
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 9 INCREASING ADOPTION OF PRECISION ONCOLOGY TO DRIVE MARKET
FIGURE 10 PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 11 ASSAYS, KITS & REAGENTS AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12 CLINICAL TUMOR PROFILING TESTING SERVICES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13 NEXT GENERATION SEQUENCING SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15 CLINICAL APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 16 CANCER DIAGNOSIS, MOLECULAR CHARACTERIZATION AND PROGNOSTIC/RISK ASSESSMENT SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 17 BIOMARKER, TARGET AND EARLY DRUG DISCOVERY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 18 SOLID TUMOR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 19 LUNG CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 20 LEUKEMIA SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 21 HOSPITALS, CANCER CENTERS AND ONCOLOGY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 22 DEDICATED CANCER HOSPITALS AND CANCER CENTERS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 24 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 25 CANCER/TUMOR PROFILING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 26 CANCER/TUMOR PROFILING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 27 CANCER/ TUMOR PROFILING MARKET: VALUE CHAIN ANALYSIS
FIGURE 28 CANCER/TUMOR PROFILING MARKET: ECOSYSTEM ANALYSIS
FIGURE 29 CANCER/TUMOR PROFILING MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 30 NUMBER OF DEALS & FUNDING ACTIVITIES OF KEY PLAYERS IN THE CANCER/TUMOR PROFILING MARKET
FIGURE 31 PATENT ANALYSIS FOR CANCER/TUMOR PROFILING MARKET, JANUARY 2016–DECEMBER 2025
FIGURE 32 MARKET POTENTIAL OF AI IN CANCER/TUMOR PROFILING MARKET
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE OFFERING
FIGURE 34 KEY BUYING CRITERIA, BY PRODUCT & SERVICE OFFERING
FIGURE 35 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 36 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER/TUMOR PROFILING MARKET, 2023–2025 (USD MILLION)
FIGURE 38 CANCER/TUMOR PROFILING MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 39 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 40 CANCER/TUMOR PROFILING MARKET: COMPANY FOOTPRINT
FIGURE 41 CANCER/TUMOR PROFILING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 42 EV/EBITDA OF KEY VENDORS
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 44 CANCER/TUMOR PROFILING MARKET: BRAND/PRODUCT COMPARISON FOR CANCER/TUMOR PROFILING
FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 49 GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
FIGURE 50 LABCORP: COMPANY SNAPSHOT (2025)
FIGURE 51 ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 52 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025)
FIGURE 53 NATERA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 54 NEOGENOMICS LABORATORIES, INC: COMPANY SNAPSHOT (2025)
FIGURE 55 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025)
FIGURE 56 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 57 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025)
FIGURE 58 CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 59 DANAHER: COMPANY SNAPSHOT (2025)
FIGURE 60 RESEARCH DESIGN
FIGURE 61 KEY DATA FROM SECONDARY SOURCES
FIGURE 62 LIST OF PRIMARY SOURCES
FIGURE 63 KEY INDUSTRY INSIGHTS
FIGURE 64 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 65 APPROACH 1: REVENUE ESTIMATION OF KEY PLAYERS
FIGURE 66 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031): IMPACT ON MARKET GROWTH AND CAGR
FIGURE 67 CAGR PROJECTIONS
FIGURE 68 TOP-DOWN APPROACH
FIGURE 69 DATA TRIANGULATION
FIGURE 70 PARAMETRIC ASSUMPTIONS
